What is the recommended treatment plan for hypertension, including lifestyle modifications and first‑line pharmacologic options?

Hypertension Treatment: Comprehensive Management Plan

For adults with confirmed hypertension (≥140/90 mmHg), initiate both lifestyle modifications and pharmacological therapy simultaneously, targeting blood pressure <130/80 mmHg in most patients, with treatment achieved within 3 months. 1

Lifestyle Modifications (Essential for All Patients)

All hypertensive patients require comprehensive lifestyle interventions, which can reduce systolic BP by 20-30 mmHg when combined 1:

• Weight reduction: Maintain BMI 18.5-24.9 kg/m², with even 10 lbs (4.5 kg) loss reducing BP by 5-20 mmHg per 10 kg lost 1

• DASH diet: Consume diet rich in fruits, vegetables, and low-fat dairy products with reduced saturated and total fat, providing 8-14 mmHg reduction 1, 2

• Sodium restriction: Limit intake to ≤100 mmol/day (2.4 g sodium or 6 g sodium chloride), achieving 2-8 mmHg reduction 1, 2

• Potassium supplementation: Increase dietary potassium through DASH diet 1, 2

• Physical activity: Engage in regular aerobic exercise (brisk walking ≥30 minutes most days), reducing BP by 4-9 mmHg 1, 2

• Alcohol moderation: Limit to ≤2 drinks/day for men, ≤1 drink/day for women (12 oz beer, 5 oz wine, or 1.5 oz spirits), achieving 2-4 mmHg reduction 1, 2

• Smoking cessation: Strongly counsel all patients to quit for overall cardiovascular risk reduction 1

Pharmacological Treatment Algorithm

Initial Therapy Selection by Patient Population

For Non-Black Patients 1:

1. Start low-dose ACE inhibitor or ARB
2. Add dihydropyridine calcium channel blocker (DHP-CCB)
3. Increase to full doses
4. Add thiazide/thiazide-like diuretic
5. Add spironolactone (or if contraindicated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker)

For Black Patients 1:

1. Start low-dose ARB + DHP-CCB or DHP-CCB + thiazide/thiazide-like diuretic
2. Increase to full doses
3. Add diuretic or ACE inhibitor/ARB
4. Add spironolactone (or alternatives as above)

Specific First-Line Drug Classes

The following are equally effective first-line agents 1, 2:

• Thiazide/thiazide-like diuretics: Chlorthalidone 12.5-25 mg daily (preferred over hydrochlorothiazide due to longer half-life and proven CVD reduction) 1

• ACE inhibitors: Lisinopril 10-40 mg daily, enalapril 5-40 mg daily, or ramipril 2.5-20 mg daily 1, 2

• ARBs: Losartan 25-100 mg daily, candesartan 8-32 mg daily, or valsartan 80-320 mg daily 1, 2

• Calcium channel blockers: Amlodipine 2.5-10 mg daily or other DHP-CCBs 1, 2

Combination Therapy Strategy

Use fixed-dose single-pill combinations whenever possible to improve adherence 1:

• Most patients require ≥2 drugs for BP control; in ALLHAT, 60% of controlled patients needed ≥2 agents 1

• For Grade 2 hypertension (≥160/100 mmHg) or BP ≥20/10 mmHg above target: initiate two-drug combination immediately 1

• Preferred initial combinations: RAS blocker (ACE inhibitor or ARB) + DHP-CCB or thiazide diuretic 1

Treatment Timing by Risk Category

High-risk patients (CVD, CKD, diabetes, organ damage, or age 50-80 years): Start pharmacotherapy immediately alongside lifestyle modifications 1

Low-moderate risk patients with Grade 1 hypertension (140-159/90-99 mmHg): Initiate lifestyle modifications; if BP remains elevated after 3-6 months, add pharmacotherapy 1

Elevated BP (130-139/85-89 mmHg) with 10-year CVD risk ≥10%: Consider pharmacotherapy with lifestyle modifications 1

Blood Pressure Targets

Standard target: <130/80 mmHg for most adults 1, 2

Special populations:

• Adults ≥65 years: SBP <130 mmHg if tolerated 1, 2
• Elderly with frailty: Individualize based on frailty status, may accept <140/90 mmHg 1
• Heart failure: Target <130/80 mmHg, consider <120/80 mmHg in selected patients 1
• Patients >80 years or frail: Consider monotherapy initially 1

Monitoring and Follow-Up

• Achieve target BP within 3 months of treatment initiation 1
• Stage 1 hypertension with high CVD risk: Reassess in 1 month 1
• Stage 2 hypertension: Reassess in 1 month 1
• Controlled hypertension: Annual follow-up 1
• Use home BP monitoring (target <135/85 mmHg) or 24-hour ambulatory monitoring (target <130/80 mmHg) to confirm office readings 1

Critical Contraindications and Cautions

Never combine 1:

• ACE inhibitor + ARB + renin inhibitor (potentially harmful)
• Two RAS blockers simultaneously

Avoid in heart failure 1:

• Non-dihydropyridine CCBs (diltiazem, verapamil) due to negative inotropic effects
• Alpha-blockers as first-line (doxazosin increased HF risk 2-fold in ALLHAT)
• Clonidine and moxonidine (increased mortality in HF)

Monitor for 1:

• Hypokalemia and hyponatremia with thiazide diuretics
• Hyperkalemia with ACE inhibitors/ARBs, especially in CKD or with potassium supplements
• Acute renal failure with ACE inhibitors/ARBs in bilateral renal artery stenosis
• Angioedema with ACE inhibitors (absolute contraindication to rechallenge)

Common Pitfalls

• Undertreatment: Only 44% of US adults with hypertension achieve <140/90 mmHg control 2
• Monotherapy failure: Do not persist with single-agent therapy when BP remains uncontrolled; escalate to combination therapy 1
• Thiazide selection: Chlorthalidone is preferred over hydrochlorothiazide for superior CVD outcomes 1
• Delayed intensification: If BP not controlled on two drugs, advance to three-drug combination (RAS blocker + DHP-CCB + thiazide diuretic) 1
• Inadequate lifestyle counseling: Lifestyle modifications enhance drug efficacy and may allow medication reduction 1, 2